Optimizing DAA management in daily practice

Digestive and Liver Disease

Volumn 45, Issue S5, 2013, Pages

  Serfaty, Lawrence ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Adherence; Anaemia; Boceprevir; Drug drug interaction; Educational nurse; Skin rash; Stopping rules; Telaprevir; Triple therapy

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; INTERLEUKIN 28B; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ADVERSE OUTCOME; ANEMIA; CHECKLIST; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DIET; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG INTERACTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADHERENCE; ANAEMIA; BOCEPREVIR; DRUG-DRUG INTERACTION; EDUCATIONAL NURSE; SKIN RASH; STOPPING RULES; TELAPREVIR; TRIPLE THERAPY;

ANTIVIRAL AGENTS; CHECKLIST; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MEDICATION ADHERENCE; OLIGOPEPTIDES; PATIENT EDUCATION AS TOPIC; POLYETHYLENE GLYCOLS; PROLINE; RIBAVIRIN;

EID: 84884710632     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.07.011     Document Type: Review

References (24)

1. EASL clinical practice guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011, 55:245-264.
2. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1195-1206.
3. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011, 364:2405-2416.
4. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
5. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1207-1217.
6. Kiser J.J., Burton J.R., Anderson P.L., et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012, 55:1620-1628.
7. Jacobson I.M., Bartels D.J., Gritz L., et al. Futility rules in telaprevir combination treatment. Journal of Hepatology 2012, 56:S24.
8. Jacobson I.M., Marcellin P., Zeuzem S., et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012, 56:567-575.
9. Jacobson I.M., Catlett I., Marcellin P., et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. Journal of Hepatology 2011, 54:S543.
10. Poordad F., Bronowicki J.P., Gordon S.C., et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143:608-618.
11. Deltenre P., Louvet A., Lemoine M., et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. Journal of Hepatology 2011, 55:1187-1194.
12. Serfaty L., Forns X., Tobias G., et al. Impact of insulin resistance on response to telaprevir in combination with peginterferon alfa and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Gut 2012, 61:1473-1480.
13. Vierling J.M., Flamm S.L., Gordon S.C., et al. Efficacy of boceprevir in prior null responders to Peg-interferon-ribavirin: the PROVIDE study. Hepatology 2011, 54:A931.
14. Berg T., Andreone P., Pol S., et al. Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peg-ifn/ribavirin failure: post-hoc analysis of the phase III REALIZE study. Hepatology 2011, 54:A32.
15. Pol S., Aerssens J., Zeuzem S., et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. Journal of Hepatology 2013, 58:883-889.
16. Gordon S.C., Lawitz E.J., Bacon B.R., et al. Adherence to assigned dosing regimen and sustained virologic response among hepatitis C genotype 1 treatment-naive and peg/ribavirin treatment-failures treated with boceprevir plus peginterferon alfa-2b/ribavirin. Journal of Hepatology 2011, 54:S173-S174.
17. Adiwijaya B.S., Kieffer T.L., Adda N., et al. Quantification the effect of adherence to clinical outcomes in telaprevir-based regimens. Global Antiviral Journal 2011, 7(Suppl 1):60.
18. Buti M., Agarwal K., Horsmans Y., et al. Optimize trial: non-inferiority of twice-daily telaprevir versus administration every 8hours in treatment-naive, genotype 1 HCV infected patients. Hepatology 2012, 56:1521A.
19. Sulkowski M., Poordad F., Manns M.P., et al. Anemia during treatment with peginterferon alfa-2B/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment failure patients. Journal of Hepatology 2011, 54:S194.
20. Reddy K.R., Shiffman M.L., Morgan T.R., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clinical Gastroenterology and Hepatology 2007, 5:124-129.
21. Sulkowski M., Reddy K.R., Afdhal N.H., et al. Anemia has no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in ADVANCE and ILLUMINATE phase 3 studies. Journal of Hepatology 2011, 54:S195.
22. Poordad F.F., Lawitz E.J., Reddy K.R., et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. Journal of Hepatology 2012, 56:A1419.
23. Lawitz E., Zeuzem S., Nyberg L.M., et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/RBV) in treatment-naïve chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response (SVR) and safety subanalyses from the anemia management study. Hepatology 2012, 56(Suppl. 1):216A.
24. Hézode C., Fontaine H., Dorival C., et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the French early access programme (anrs co20-cupic) - nct01514890. Journal of Hepatology 2013, 59:434-441.